BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Bossi P, Antonuzzo A, Cherny NI, Rosengarten O, Pernot S, Trippa F, Schuler U, Snegovoy A, Jordan K, Ripamonti CI; ESMO Guidelines Committee. Diarrhoea in adult cancer patients: ESMO Clinical Practice Guidelines. Ann Oncol. 2018;29:iv126-iv142. [PMID: 29931177 DOI: 10.1093/annonc/mdy145] [Cited by in Crossref: 29] [Cited by in F6Publishing: 24] [Article Influence: 9.7] [Reference Citation Analysis]
Number Citing Articles
1 Kordes M, Gerling M. Variations in the management of diarrhoea induced by cancer therapy: results from an international, cross-sectional survey among European oncologists. ESMO Open 2019;4:e000607. [PMID: 31803505 DOI: 10.1136/esmoopen-2019-000607] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
2 Vuattoux D, Colomer-Lahiguera S, Fernandez PA, Jequier Gygax M, Choucair ML, Beck-Popovic M, Diezi M, Manificat S, Latifyan S, Ramelet AS, Eicher M, Chabane N, Renella R. Cancer Care of Children, Adolescents and Adults With Autism Spectrum Disorders: Key Information and Strategies for Oncology Teams. Front Oncol 2020;10:595734. [PMID: 33552969 DOI: 10.3389/fonc.2020.595734] [Reference Citation Analysis]
3 Khan MS, Walter T, Buchanan-Hughes A, Worthington E, Keeber L, Feuilly M, Grande E. Differential diagnosis of diarrhoea in patients with neuroendocrine tumours: A systematic review. World J Gastroenterol 2020; 26(30): 4537-4556 [PMID: 32874063 DOI: 10.3748/wjg.v26.i30.4537] [Cited by in CrossRef: 4] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
4 Schwartz G, Darling JO, Mindo M, Damicis L. Management of Adverse Events Associated with Cabozantinib Treatment in Patients with Advanced Hepatocellular Carcinoma. Target Oncol 2020;15:549-65. [PMID: 32770441 DOI: 10.1007/s11523-020-00736-8] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.5] [Reference Citation Analysis]
5 Popescu RA, Roila F, Arends J, Metro G, Lustberg M. Supportive Care: Low Cost, High Value. Am Soc Clin Oncol Educ Book 2021;41:1-11. [PMID: 33830830 DOI: 10.1200/EDBK_320041] [Reference Citation Analysis]
6 Sanz-Paris A, Martinez-García M, Martinez-Trufero J, Lambea-Sorrosal J, Calvo-Gracia F, López-Alaminos ME. Oligomeric Enteral Nutrition in Undernutrition, due to Oncology Treatment-Related Diarrhea. Systematic Review and Proposal of An Algorithm of Action. Nutrients 2019;11:E1888. [PMID: 31412681 DOI: 10.3390/nu11081888] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
7 Labadie BW, Morris DS, Bryce AH, Given R, Zhang J, Abida W, Chowdhury S, Patnaik A. Guidelines for Management of Treatment-Emergent Adverse Events During Rucaparib Treatment of Patients with Metastatic Castration-Resistant Prostate Cancer. CMAR 2022;Volume 14:673-86. [DOI: 10.2147/cmar.s335962] [Reference Citation Analysis]
8 Juarso E, Kiehl M, Buchholz M, Weißinger F. [Infections as oncologic emergencies]. Onkologe (Berl) 2020;26:129-38. [PMID: 32288312 DOI: 10.1007/s00761-019-00691-8] [Reference Citation Analysis]
9 Wei MT, Scapa J, Bingham D, Triadafilopoulos G. Gut Dysthymia: Paraneoplastic Chronic Watery Diarrhea. Dig Dis Sci 2020;65:2217-20. [PMID: 31965390 DOI: 10.1007/s10620-020-06058-z] [Reference Citation Analysis]
10 Lorusso D, García-Donas J, Sehouli J, Joly F. Management of Adverse Events During Rucaparib Treatment for Relapsed Ovarian Cancer: A Review of Published Studies and Practical Guidance. Target Oncol 2020;15:391-406. [PMID: 32495160 DOI: 10.1007/s11523-020-00715-z] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
11 Fernandes DC, Jervoise N Andreyev H. Chronic diarrhoea in an oncology patient - Clinical assessment and decision making. Best Pract Res Clin Gastroenterol 2020;48-49:101708. [PMID: 33317791 DOI: 10.1016/j.bpg.2020.101708] [Reference Citation Analysis]
12 Biganzoli L, Battisti NML, Wildiers H, McCartney A, Colloca G, Kunkler IH, Cardoso MJ, Cheung KL, de Glas NA, Trimboli RM, Korc-Grodzicki B, Soto-Perez-de-Celis E, Ponti A, Tsang J, Marotti L, Benn K, Aapro MS, Brain EGC. Updated recommendations regarding the management of older patients with breast cancer: a joint paper from the European Society of Breast Cancer Specialists (EUSOMA) and the International Society of Geriatric Oncology (SIOG). Lancet Oncol 2021;22:e327-40. [PMID: 34000244 DOI: 10.1016/S1470-2045(20)30741-5] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
13 Garczyk A, Kaliciak I, Drogowski K, Horwat P, Kopeć S, Staręga Z, Bogdański P, Stelmach-Mardas M, Mardas M. Influence of Probiotics in Prevention and Treatment of Patients Who Undergo Chemotherapy or/and Radiotherapy and Suffer from Mucositis, Diarrhoea, Constipation, Nausea and Vomiting. J Clin Med 2022;11:3412. [PMID: 35743481 DOI: 10.3390/jcm11123412] [Reference Citation Analysis]
14 Smith P, Lavery A, Turkington RC. An overview of acute gastrointestinal side effects of systemic anti-cancer therapy and their management. Best Pract Res Clin Gastroenterol 2020;48-49:101691. [PMID: 33317796 DOI: 10.1016/j.bpg.2020.101691] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
15 Andreyev HJN, Lalji A, Mohammed K, Muls ACG, Watkins D, Rao S, Starling N, Chau I, Cruse S, Pitkaaho V, Matthews J, Caley L, Pittordou V, Adams C, Wedlake L. The FOCCUS study: a prospective evaluation of the frequency, severity and treatable causes of gastrointestinal symptoms during and after chemotherapy. Support Care Cancer 2021;29:1443-53. [PMID: 32676853 DOI: 10.1007/s00520-020-05610-x] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
16 Ciruelos EM, Rugo HS, Mayer IA, Levy C, Forget F, Delgado Mingorance JI, Safra T, Masuda N, Park YH, Juric D, Conte P, Campone M, Loibl S, Iwata H, Zhou X, Park J, Ridolfi A, Lorenzo I, André F. Patient-Reported Outcomes in Patients With PIK3CA-Mutated Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer From SOLAR-1. J Clin Oncol 2021;39:2005-15. [PMID: 33780274 DOI: 10.1200/JCO.20.01139] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
17 Harder H, Shilling VM, May SF, Cella D, Schmid P, Fallowfield LJ. The development and initial evaluation of the Diarrhoea Management Diary (DMD) in patients with metastatic breast cancer. Breast Cancer Res Treat 2020;183:629-38. [PMID: 32720113 DOI: 10.1007/s10549-020-05798-w] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
18 Juarso AE, Kiehl M, Buchholz M, Weißinger F. [Infections as oncologic emergencies]. Wien Klin Mag 2020;:1-8. [PMID: 32322312 DOI: 10.1007/s00740-020-00339-z] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
19 Dhillon S. Neratinib in Early-Stage Breast Cancer: A Profile of Its Use in the EU. Clin Drug Investig 2019;39:221-9. [PMID: 30607817 DOI: 10.1007/s40261-018-0741-2] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.7] [Reference Citation Analysis]
20 Gupta A, Nshuti L, Grewal US, Sedhom R, Check DK, Parsons HM, Blaes AH, Virnig BA, Lustberg MB, Subbiah IM, Nipp RD, Dy SM, Dusetzina SB. Financial Burden of Drugs Prescribed for Cancer-Associated Symptoms. JCO Oncol Pract 2021;:OP2100466. [PMID: 34558297 DOI: 10.1200/OP.21.00466] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
21 Grimm M, Bex A, De Santis M, Ljungberg B, Catto JW, Rouprêt M, Hussain SA, Bellmunt J, Powles T, Wirth M, Van Poppel H. Safe Use of Immune Checkpoint Inhibitors in the Multidisciplinary Management of Urological Cancer: The European Association of Urology Position in 2019. European Urology 2019;76:368-80. [DOI: 10.1016/j.eururo.2019.05.041] [Cited by in Crossref: 21] [Cited by in F6Publishing: 18] [Article Influence: 7.0] [Reference Citation Analysis]
22 Janni W, Schneeweiss A, Müller V, Wöckel A, Lux MP, Hartkopf AD, Nabieva N, Taran FA, Tesch H, Overkamp F, Lüftner D, Belleville E, Schütz F, Fasching PA, Fehm TN, Kolberg HC, Ettl J. Update Breast Cancer 2019 Part 2 - Implementation of Novel Diagnostics and Therapeutics in Advanced Breast Cancer Patients in Clinical Practice. Geburtshilfe Frauenheilkd 2019;79:268-80. [PMID: 30880825 DOI: 10.1055/a-0842-6661] [Cited by in Crossref: 11] [Cited by in F6Publishing: 8] [Article Influence: 3.7] [Reference Citation Analysis]
23 Biganzoli L, Cinieri S, Berardi R, Pedersini R, McCartney A, Minisini AM, Caremoli ER, Spazzapan S, Magnolfi E, Brunello A, Risi E, Palumbo R, Leo S, Colleoni M, Donati S, De Placido S, Orlando L, Pistelli M, Parolin V, Mislang A, Becheri D, Puglisi F, Sanna G, Zafarana E, Boni L, Mottino G. EFFECT: a randomized phase II study of efficacy and impact on function of two doses of nab-paclitaxel as first-line treatment in older women with advanced breast cancer. Breast Cancer Res 2020;22:83. [PMID: 32758299 DOI: 10.1186/s13058-020-01319-1] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
24 Moschen AR, Sammy Y, Marjenberg Z, Heptinstall AB, Pooley N, Marczewska AM. The Underestimated and Overlooked Burden of Diarrhea and Constipation in Cancer Patients. Curr Oncol Rep 2022. [PMID: 35325401 DOI: 10.1007/s11912-022-01267-3] [Reference Citation Analysis]
25 Senderovich H, Vierhout M. Is There a Role for Bismuth in Diarrhea Management? Rambam Maimonides Med J 2021;12. [PMID: 33064636 DOI: 10.5041/RMMJ.10422] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
26 Dudzisz-Śledź M, Bylina E, Teterycz P, Rutkowski P. Treatment of Metastatic Gastrointestinal Stromal Tumors (GIST): A Focus on Older Patients. Drugs Aging 2021;38:375-96. [PMID: 33651369 DOI: 10.1007/s40266-021-00841-x] [Reference Citation Analysis]
27 Anthony LB, O'Dorisio TM. Opportunities to Improve Symptom Control with Somatostatin Congeners in GEP-NETs: A Review of Key Issues. Oncologist 2021;26:e1171-8. [PMID: 34097784 DOI: 10.1002/onco.13847] [Reference Citation Analysis]
28 Shahid RK, Ahmed S, Le D, Yadav S. Diabetes and Cancer: Risk, Challenges, Management and Outcomes. Cancers (Basel) 2021;13:5735. [PMID: 34830886 DOI: 10.3390/cancers13225735] [Reference Citation Analysis]
29 Costa DVS, Costa DVS, Sousa CNS, Silva AMHP, Medeiros IS, Martins DS, Martins CS, Pequeno ALV, Lima-Júnior RCP, Soares PMG, Vasconcelos SMM, Brito GAC, Souza EP. The Alpha-Lipoic Acid Improves Survival and Prevents Irinotecan-Induced Inflammation and Intestinal Dysmotility in Mice. Pharmaceuticals (Basel) 2020;13:E361. [PMID: 33152996 DOI: 10.3390/ph13110361] [Reference Citation Analysis]
30 Diaz R, Kober KM, Viele C, Cooper BA, Paul SM, Hammer M, Wright F, Conley YP, Levine JD, Miaskowski C. Distinct diarrhea profiles during outpatient chemotherapy. Support Care Cancer 2021;29:2363-73. [PMID: 32918132 DOI: 10.1007/s00520-020-05753-x] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
31 Modi ND, Abuhelwa AY, Badaoui S, Shaw E, Shankaran K, McKinnon RA, Rowland A, Sorich MJ, Hopkins AM. Prediction of severe neutropenia and diarrhoea in breast cancer patients treated with abemaciclib. Breast 2021;58:57-62. [PMID: 33906086 DOI: 10.1016/j.breast.2021.04.003] [Reference Citation Analysis]
32 Stie M, Delmar C, Nørgaard B, Jensen LH. Impact of Open Dialogue about Complementary Alternative Medicine-A Phase II Randomized Controlled Trial. Cancers (Basel) 2022;14:952. [PMID: 35205698 DOI: 10.3390/cancers14040952] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]